论文部分内容阅读
目的:分析瑞舒伐他汀钙用于慢性肾病患者降血脂的效果及安全性。方法:选取我院2010年3月-2014年3月期间,我院收治的82例慢性肾病患者为研究对象,采用数字随机分组方式将其均分为观察组41例以及对照组41例,其中观察组患者给予瑞舒伐他汀钙治疗;对照组给予阿托伐他汀钙治疗,对比分析两组患者(TC)总胆固醇、TG(三酰甘油)LDL-C(低密度脂蛋白胆固醇)以及HDL-C(高密度脂蛋白胆固醇)。结果:在经过不同治疗后,观察组患者无论是TC、TG、HDL-C以及LDL-C等各项指标均优于对照组(P<0.05),具备显著差异。结论:在对慢性肾病患者进行治疗的过程中,选择采用瑞舒伐他汀钙治疗效果将明显优于阿托伐他汀钙,能对患者的血脂水平起到很好的改善作用,在临床中值得推广使用。
Objective: To analyze the effect and safety of rosuvastatin calcium on lowering blood lipid in patients with chronic kidney disease. Methods: From March 2010 to March 2014 in our hospital, 82 patients with chronic kidney disease treated in our hospital were enrolled in this study. They were randomly divided into observation group (41 cases) and control group (41 cases) Patients in the observation group were given rosuvastatin calcium; those in the control group were given atorvastatin calcium. The levels of total cholesterol (TC), TG (triglyceride) LDL-C (low density lipoprotein cholesterol) and HDL -C (high-density lipoprotein cholesterol). Results: After treatment, the indexes of TC, TG, HDL-C and LDL-C in observation group were better than those in control group (P <0.05), with significant difference. Conclusion: In the treatment of patients with chronic kidney disease, the choice of rosuvastatin calcium treatment will be significantly superior to atorvastatin calcium, can play a good role in improving the patient’s blood lipids in the clinical worth Promote use.